Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV

References

• https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/number-of-people-(all-ages)-living-with-hiv
   Google Scholar
• Heidary M, Nasiri MJ, Mirsaeidi M, et al. Mycobacterium avium complex infection in patients with human immunodeficiency virus: a systematic review and meta‐analysis. J Cell Physiol. 2019;234(7):9994–10001. https://doi.org/https://doi.org/10.1002/jcp.27859.
   PubMedGoogle Scholar
• Weichseldorfer M, Reitz M, Latinovic OS. Past HIV-1 medications and the current status of combined antiretroviral therapy options for HIV-1 patients. Pharmaceutics. 2021;13(11):1798.
   PubMed Web of Science ®Google Scholar
• Labh R, Gupta R. Emerging trends in the long-acting antiretroviral therapy: current status and therapeutic challenges. Curr HIV Res. 2021;19(1):4–13.
   PubMedGoogle Scholar
• Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022;17(1):22–31.
   PubMedGoogle Scholar
• Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Inter Assoc Providers of AIDS Care (JIAPAC). 2021;20:23259582211009011. https://doi.org/https://doi.org/10.1177/23259582211009011.
   Google Scholar
• Eggleton JS, Nagalli S. Highly active antiretroviral therapy (HAART). 2020.
   Google Scholar
• Heidary M, Nasiri MJ. Why has HIV/AIDS prevalence increased in Iran? Clin Infect Dis. 2016;63(6):846.
   PubMed Web of Science ®Google Scholar
• Silva B, Peixoto G, da Luz S, et al. Adverse effects of chronic treatment with the main subclasses of highly active antiretroviral therapy: a systematic review. HIV Med. 2019;20(7):429–438.
   PubMed Web of Science ®Google Scholar
• Durham SH, Chahine EB. Cabotegravir-rilpivirine: the first complete long-acting injectable regimen for the treatment of HIV-1 infection. Ann Pharmacother. 2021;55(11):1397–1409.
   PubMedGoogle Scholar
• Kovač L, Časar Z. A literature review of the patent application publications on cabotegravir–an HIV integrase strand transfer inhibitor. Expert Opin Ther Pat. 2020;30(3):195–208.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510. https://doi.org/https://doi.org/10.1016/S0140-6736(17)31917-7.
   PubMed Web of Science ®Google Scholar
• Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397–406. https://doi.org/https://doi.org/10.1128/AAC.03909-14.
   PubMed Web of Science ®Google Scholar
• Rial-Crestelo D, Pinto-Martínez A, Pulido F. Cabotegravir and rilpivirine for the treatment of HIV. Expert Rev Anti Infect Ther. 2020;18(5):393–404.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA news release. 2021 cited 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention
   Google Scholar
• Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68(2):250–256.
   PubMed Web of Science ®Google Scholar
• Markham A. Cabotegravir plus rilpivirine: first approval. Drugs. 2020;80(9):915–922.
   PubMed Web of Science ®Google Scholar
• Leonard A, Broussard J, Wilson N, et al. Cabotegravir and rilpivirine: a long-acting injectable antiretroviral treatment for human immunodeficiency virus. J Nurse Practit. 2022;18(1):17–21.
   Google Scholar
• PHAR W, Combinations A-H Antivirals: HIV–Cabotegravir/rilpivirine (Cabenuva).
   Google Scholar
• Hodge D, Back DJ, Gibbons S, et al. Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60(7):835–53.
   PubMedGoogle Scholar
• Letendre SL, Mills A, Hagins D, et al. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. J Antimicrob Chemother. 2020;75(3):648–655. https://doi.org/https://doi.org/10.1093/jac/dkz504.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 54713659. Cabotegravir. 2022.
   Google Scholar
• Canetti D, Spagnuolo V. An evaluation of cabotegravir for HIV treatment and prevention. Expert Opin Pharmacother. 2021;22(4):403–414.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu S-X, He Q, et al. Advances in the development of HIV integrase strand transfer inhibitors. Eur J Med Chem. 2021;225:113787.
   PubMedGoogle Scholar
• Healthcare V. Cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension (Cabenuva) Prescribing Information. US; 2021 January.
   Google Scholar
• Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2, 6-dimethylphenyl] amino]-2-pyrimidinyl] amino] benzonitrile (R278474, rilpivirine). J Med Chem. 2005;48(6):1901–1909. https://doi.org/https://doi.org/10.1021/jm040840e.
   PubMed Web of Science ®Google Scholar
• Miller CD, Crain J, Tran B, et al. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs of Today (Barcelona, Spain : 1998). 2011;47(1):5–15.
   PubMed Web of Science ®Google Scholar
• Das K, Bauman JD, Clark AD, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Nat Acad Sci. 2008;105(5):1466–1471. https://doi.org/https://doi.org/10.1073/pnas.0711209105.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Li D, et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem. 2011;18(3):359–376.
   PubMed Web of Science ®Google Scholar
• Cunha RF, Simões S, Carvalheiro M, et al. Novel antiretroviral therapeutic strategies for HIV. Molecules. 2021;26(17):5305.
   PubMedGoogle Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–650. https://doi.org/https://doi.org/10.1126/science.287.5453.646.
   PubMed Web of Science ®Google Scholar
• Jóźwik IK, Passos DO, Lyumkis D. Structural biology of HIV integrase strand transfer inhibitors. Trends Pharmacol Sci. 2020;41(9):611–626.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C. Pharmacokinetics and pharmacodynamics of cabotegravir, a long-acting HIV integrase strand transfer inhibitor. Eur J Drug Metab Pharmacokinet. 2019;44(3):319–327.
   PubMed Web of Science ®Google Scholar
• Properzi M, Magro P, Castelli F, et al. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev Anti Infect Ther. 2018;16(12):877–887.
   PubMed Web of Science ®Google Scholar
• Sanford M. Rilpivirine. Drugs. 2012;72(4):525–541.
   PubMed Web of Science ®Google Scholar
• Mbhele N, Chimukangara B, Gordon M. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke TR, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):1–18.
   PubMedGoogle Scholar
• Smith RA, Wu VH, Zavala CG, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother. 2018;62(10):e01299–18. https://doi.org/https://doi.org/10.1128/AAC.01299-18.
   PubMedGoogle Scholar
• Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009;18(7):1035–1041.
   PubMed Web of Science ®Google Scholar
• Healthcare V. Cabenuva prescribing information [Internet]. January 2021. Available from: (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf)
   Google Scholar
• DeHaan E, McGowan JP, Fine SM, et al. Use of Injectable CAB/RPV LA as replacement art in virally suppressed adults with HIV. 2021.
   Google Scholar
• Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e40. https://doi.org/https://doi.org/10.1016/S2352-3018(17)30068-1.
   PubMed Web of Science ®Google Scholar
• Beyrer C, Pozniak A. HIV drug resistance—an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–1607.
   PubMed Web of Science ®Google Scholar
• Cook NJ, Li W, Berta D, et al. Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science. 2020;367(6479):806–810. https://doi.org/https://doi.org/10.1126/science.aay4919.
   PubMedGoogle Scholar
• Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278–a novel NNRTI–in treatment-naive HIV-1-infected subjects. Aids. 2006;20(13):1721–1726. https://doi.org/https://doi.org/10.1097/01.aids.0000242818.65215.bd.
   PubMed Web of Science ®Google Scholar
• FDA Label for EDURANTTM (Rilpivirine) tablets [Package Insert]. (15 June 2012, date last accessed).
   Google Scholar
• McPherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of human immunodeficiency virus-1. Expert Opin Investig Drugs. 2018;27(4):413–420.
   PubMed Web of Science ®Google Scholar
• Calvez V, Marcelin A-G, Vingerhoets J, et al. Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons. Antivir Ther. 2016;21(5):405–412.
   PubMedGoogle Scholar
• Schafer JJ, Short WR. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Antivir Ther. 2012;17(8):1495–1502.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145–1155. https://doi.org/https://doi.org/10.1016/S1473-3099(15)00152-8.
   PubMed Web of Science ®Google Scholar
• Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–1135. https://doi.org/https://doi.org/10.1056/NEJMoa1909512.
   PubMed Web of Science ®Google Scholar
• H V. Study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current antiretroviral regimen in virologically suppressed HIV-1-infected adults. ClinicalTrials.gov. 2019 cited 2019 Dec 15; Published.
   Google Scholar
• Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396(10267):1994–2005. https://doi.org/https://doi.org/10.1016/S0140-6736(20)32666-0.
   PubMed Web of Science ®Google Scholar
• Cutrell AG, Schapiro JM, Perno CF, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS (London England). AIDS (London, England). 2021;35(9):1333. https://doi.org/https://doi.org/10.1097/QAD.0000000000002883.
   PubMed Web of Science ®Google Scholar
• Spreen W, Min S, Ford S, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192–203. https://doi.org/https://doi.org/10.1310/hct1405-192.
   PubMed Web of Science ®Google Scholar
• Patel P, Ford SL, Crauwels H, et al. editors. 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infect Dis. 2019;6(Supplement_2):S865–S866. https://doi.org/https://doi.org/10.1093/ofid/ofz360.2173.
   Google Scholar
• Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 study. In: Smith GH, Henry WK, Podzamczer D, et al., editor. Open forum infectious diseases. Oxford University Press US; 2021.
   Google Scholar
• Bowers GD, Culp A, Reese MJ, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147–162. https://doi.org/https://doi.org/10.3109/00498254.2015.1060372.
   PubMed Web of Science ®Google Scholar
• Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445–456. https://doi.org/https://doi.org/10.3109/00498254.2015.1081993.
   PubMed Web of Science ®Google Scholar
• Taskar KS, Patel A, Cozens SJ, et al., editors. Prediction of renal OAT1 and OAT3 inhibition by cabotegravir using pbpk modelling. Conference on Retroviruses and Opportunistic Infections; 2019.
   Google Scholar
• McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance. Infect Dis Clin. 2019;33(3):707–742.
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–727. https://doi.org/https://doi.org/10.1128/AAC.00986-09.
   PubMed Web of Science ®Google Scholar
• Hoetelmans R, Kestens D, Marien K, et al., editors. Effect of food and multiple dose pharmacokinetics of TMC278 as an oral tablet formulation. Abstract TuPe3 1B10, presented at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005.
   Google Scholar
• Mora-Peris B, Watson V, Vera JH, et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. J Antimicrob Chemother. 2014;69(6):1642–1647. https://doi.org/https://doi.org/10.1093/jac/dku018.
   PubMed Web of Science ®Google Scholar
• Jackson A, Else L, Mesquita P, et al. A compartmental pharmacokinetic evaluation of long‐acting rilpivirine in HIV‐negative volunteers for pre‐exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314–323. https://doi.org/https://doi.org/10.1038/clpt.2014.118.
   PubMed Web of Science ®Google Scholar
• Maggi P, Montinaro V, Mussini C, et al. Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Rev. 2014;16(3):144–151.
   PubMedGoogle Scholar
• Alexander K. Dosage forms and their routes of administration. Pharmacology: Elsevier; 2009. p. 9–29.
   Google Scholar
• Crauwels H, Van Heeswijk R, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15(2):87–101.
   PubMed Web of Science ®Google Scholar
• Demessine L, Peyro-Saint-Paul L, Gardner EM, et al., editors. Risk and cost associated with drug–drug interactions among aging HIV patients receiving combined antiretroviral therapy in France. Open forum infectious diseases. Oxford University Press US; 2019.
   Google Scholar
• Sang Y, Ding L, Zhuang C, et al. Design strategies for long-acting anti-HIV pharmaceuticals. Curr Opin Pharmacol. 2020;54:158–165.
   PubMed Web of Science ®Google Scholar
• Van Heeswijk R, Hoetelmans R, Kestens D, et al., editors. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 7th International Workshop of Clinical Pharmacology; 2006.
   Google Scholar
• Fernandez C, van Halsema CL. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS. Vol. 11. Auckland NZ 2019.179
   Google Scholar
• Blair CS, Li S, Chau G, et al. Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquired Immune Deficiency Syndromes. 2020;85(1):93. https://doi.org/https://doi.org/10.1097/QAI.0000000000002409. 1999.
   PubMedGoogle Scholar
• Rajoli RK, Curley P, Chiong J, et al. Predicting drug–drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis. 2019;219(11):1735–1742. https://doi.org/https://doi.org/10.1093/infdis/jiy726.
   PubMedGoogle Scholar
• Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112–1123. https://doi.org/https://doi.org/10.1056/NEJMoa1904398.
   PubMed Web of Science ®Google Scholar
• Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8(11):e679–e89. https://doi.org/https://doi.org/10.1016/S2352-3018(21)00185-5.
   PubMed Web of Science ®Google Scholar
• Heidary M, Asadi A, Noorbakhsh N, et al. COVID‐19 in HIV‐positive patients: a systematic review of case reports and case series. J Clin Lab Anal. 2022;36(4):e24308. https://doi.org/https://doi.org/10.1002/jcla.24308.
   PubMedGoogle Scholar
• Rintamaki L, Kosenko K, Hogan T, et al. The role of stigma management in HIV treatment adherence. Int J Environ Res Public Health. 2019;16(24):5003. https://doi.org/https://doi.org/10.3390/ijerph16245003.
   PubMed Web of Science ®Google Scholar
• Akinwunmi B, Buchenberger D, Scherzer J, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries. Sex Transm Infect. 2021;97(8):566–573. https://doi.org/https://doi.org/10.1136/sextrans-2020-054648.
   PubMedGoogle Scholar
• Han K, Patel P, Baker M, et al., editors. Population pharmacokinetics of cabotegravir in healthy adult subjects and HIV-1 infected patients following administration of oral tablet and long-acting intramuscular injection. Poster presented at 22nd International AIDS Conference; 2018.
   Google Scholar
• Patel P, Ford S, Crauwels H, et al. Pharmacokinetics of cabotegravir and rilpivirine long-acting injectables in HIV-infected individuals through 48 weeks in the FLAIR and ATLAS phase 3 studies. Poster presented at IDWeek. 2019:2–6.
   Google Scholar
• Ford S, Crauwels H, Han K, Rossenu S, Zhang F, Huang J, et al., editors. Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation. Abstract presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 2020.
   Google Scholar